Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Novacyt ( (FR:ALNOV) ) has issued an announcement.
Novacyt S.A. has announced that its Annual General Meeting will be held in person on 19 June 2025 at the Hilton Hotel, Paris Charles de Gaulle Airport, France. The meeting will be recorded and made available on the company’s website. This announcement underscores Novacyt’s commitment to engaging with its stakeholders and maintaining transparency in its operations, potentially impacting its market presence and investor relations positively.
More about Novacyt
Novacyt is an international molecular diagnostics company that offers a wide range of integrated technologies and services, focusing on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation for sectors such as human health, animal health, and environmental. It operates through three business segments: Clinical, Instrumentation, and Research Use Only, providing products and services like in vitro diagnostic products, DNA sample preparation platforms, and qPCR assays. Novacyt is headquartered in France with offices in the UK, Singapore, the US, and Canada, and is listed on the London Stock Exchange’s AIM market and the Paris Stock Exchange Euronext Growth.
YTD Price Performance: -20.36%
Average Trading Volume: 102,017
Technical Sentiment Signal: Sell
Current Market Cap: £27.32M
For an in-depth examination of ALNOV stock, go to TipRanks’ Stock Analysis page.